Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Mar. 21, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0000086115 | ||
Entity Registrant Name | SAFEGUARD SCIENTIFICS INC | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Transition Report | false | ||
Entity File Number | 1-5620 | ||
Entity Incorporation, State or Country Code | PA | ||
Entity Tax Identification Number | 23-1609753 | ||
Entity Address, Address Line One | 150 N. Radnor Chester Road | ||
Entity Address, City or Town | Radnor | ||
Entity Address, State or Province | PA | ||
Entity Address, Postal Zip Code | 19087 | ||
City Area Code | 610 | ||
Local Phone Number | 293-0600 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | Yes | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 21,248,137 | ||
Entity Common Stock, Shares Outstanding | 16,722,994 | ||
Auditor Firm ID | 248 | ||
Auditor Name | GRANT THORNTON LLP | ||
Auditor Location | Philadelphia, Pennsylvania |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current Assets: | ||
Cash and cash equivalents | $ 9,498 | $ 13,331 |
Restricted cash | 19 | 25 |
Marketable securities | 0 | 5,956 |
Ownership interests | 0 | 860 |
Prepaid expenses and other current assets | 394 | 1,251 |
Total current assets | 9,911 | 21,423 |
Right-of-use asset, net | 971 | 1,290 |
Ownership interests and advances | 11,691 | 14,545 |
Other assets | 263 | 434 |
Total Assets | 22,836 | 37,692 |
Current Liabilities: | ||
Accounts payable | 107 | 16 |
Accrued compensation and benefits | 854 | 507 |
Accrued expenses and other current liabilities | 596 | 865 |
Lease liability - current | 489 | 429 |
Total current liabilities | 2,046 | 1,817 |
Lease liability - non-current | 760 | 1,249 |
Other long-term liabilities | 50 | 50 |
Total Liabilities | 2,856 | 3,116 |
Commitments and contingencies (Note 11) | ||
Equity: | ||
Preferred stock, $0.10 par value; 1,000 shares authorized | 0 | 0 |
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 issued at December 31, 2023 and 2022, respectively | 2,157 | 2,157 |
Additional paid-in capital | 793,992 | 804,752 |
Treasury stock, at cost; 4,947 and 5,478 shares at December 31, 2023 and 2022, respectively | (42,418) | (48,410) |
Accumulated deficit | (733,726) | (723,898) |
Accumulated other comprehensive loss | (25) | (25) |
Total Equity | 19,980 | 34,576 |
Total Liabilities and Equity | $ 22,836 | $ 37,692 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Preferred stock, par value (in dollars per share) | $ 0.1 | $ 0.1 |
Preferred stock, shares authorized (in shares) | 1,000 | 1,000 |
Common stock, par value (in dollars per share) | $ 0.1 | $ 0.1 |
Common stock, shares authorized (in shares) | 83,333 | 83,333 |
Common stock, shares issued (in shares) | 21,573 | 21,573 |
Treasury stock, shares (in shares) | 4,947 | 5,478 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
General and administrative expense | $ 5,683 | $ 4,775 |
Operating loss | (5,683) | (4,775) |
Other income (loss), net | 2,037 | (3,297) |
Interest income | 903 | 794 |
Equity (loss), net | (7,085) | (6,985) |
Net (loss) before income taxes | (9,828) | (14,263) |
Income tax benefit (expense) | 0 | 0 |
Net (loss) | $ (9,828) | $ (14,263) |
Net (loss) per share: | ||
Basic (in dollars per share) | $ (0.61) | $ (0.87) |
Diluted (in dollars per share) | $ (0.61) | $ (0.87) |
Weighted average shares used in computing net (loss) per share: | ||
Basic (in shares) | 16,221 | 16,337 |
Diluted (in shares) | 16,221 | 16,337 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Treasury Stock, Common [Member] | Total |
Balance at Dec. 31, 2021 | $ (709,635) | $ (25) | $ 2,157 | $ 806,638 | $ (48,569) | $ 50,566 |
Balance (in shares) at Dec. 31, 2021 | 21,573 | 5,068 | ||||
Net (loss) | (14,263) | 0 | $ 0 | 0 | $ 0 | (14,263) |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | (2,622) | $ 3,099 | 477 |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) | 0 | (302) | ||||
Stock-based compensation | 0 | 0 | $ 0 | 736 | $ 0 | 736 |
Repurchases of common stock | 0 | 0 | $ 0 | 0 | $ (2,940) | (2,940) |
Repurchases of common stock (in shares) | 0 | 712 | ||||
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | 2,622 | $ (3,099) | (477) |
Balance at Dec. 31, 2022 | (723,898) | (25) | $ 2,157 | 804,752 | $ (48,410) | 34,576 |
Balance (in shares) at Dec. 31, 2022 | 21,573 | 5,478 | ||||
Net (loss) | (9,828) | 0 | $ 0 | 0 | $ 0 | (9,828) |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | 5,621 | $ (6,067) | (446) |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) | 0 | (556) | ||||
Stock-based compensation | 0 | 0 | $ 0 | 680 | $ 0 | 680 |
Repurchases of common stock | 0 | 0 | $ 0 | 0 | $ (75) | (75) |
Repurchases of common stock (in shares) | 0 | 25 | ||||
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | (5,621) | $ 6,067 | 446 |
Dividends paid | 0 | 0 | 0 | 0 | (5,819) | |
Dividends paid | (5,819) | |||||
Balance at Dec. 31, 2023 | $ (733,726) | $ (25) | $ 2,157 | $ 793,992 | $ (42,418) | $ 19,980 |
Balance (in shares) at Dec. 31, 2023 | 21,573 | 4,947 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash Flows from Operating Activities: | ||
Net (loss) | $ (9,828) | $ (14,263) |
Adjustments to reconcile to net cash used in operating activities: | ||
Amortization of right of use asset | 319 | 271 |
Equity (income) loss, net | 6,085 | 6,985 |
Impairments of ownership interests and advances | 1,173 | 0 |
Gain from observable price changes | (1,661) | (553) |
Gain from sales of ownership interests | (542) | 0 |
Change in fair value of ownership interests | 0 | 3,689 |
Other, net | (7) | 76 |
Stock-based compensation, including liability classified awards | 1,121 | 1,445 |
Changes in assets and liabilities: | ||
Prepaid expenses and other current assets | (146) | (534) |
Accounts payable, accrued expenses, and other current liabilities | 178 | (374) |
Net cash used in operating activities | (3,308) | (3,258) |
Cash Flows from Investing Activities: | ||
Acquisitions of ownership interests | (3,000) | 0 |
Proceeds from sales and distributions from ownership interests | 2,851 | 6,879 |
Advances and loans to ownership interests | (250) | (5,670) |
Purchase of marketable securities | (8,530) | (11,871) |
Proceeds from sales and maturities in marketable securities | 14,650 | 6,000 |
Net cash provided by (used in) investing activities | 5,721 | (4,662) |
Cash Flows from Financing Activities: | ||
Payment of dividend | (5,819) | 0 |
Repurchases of common stock | (75) | (2,939) |
Tax withholdings related to equity-based awards | (358) | (549) |
Net cash used in financing activities | (6,252) | (3,488) |
Net change in cash, cash equivalents and restricted cash | (3,839) | (11,408) |
Cash, cash equivalents and restricted cash equivalents at beginning of year | 13,356 | 24,764 |
Cash, cash equivalents and restricted cash at end of year | $ 9,517 | $ 13,356 |
Note 1 - General
Note 1 - General | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Liquidity And Capital Resources As of December 31, 2023 In January 2018, may The Company believes that its cash and cash equivalents at December 31, 2023 one Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Safeguard and all of its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Principles of Accounting for Ownership Interests in Companies The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not third one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not not The Company accounts for ownership interests that are not December 31, 2023 no Comprehensive Income (loss) During the years ended December 31, 2023 2022, no Accounting Estimates The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2023 not no not not Cash and Cash Equivalents The Company considers all highly liquid instruments with an original maturity of 90 not not Restricted Cash Restricted cash represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Cash Flows: December 31, 2023 December 31, 2022 (In thousands) Cash and cash equivalents $ 9,498 $ 13,331 Restricted cash 19 25 Total cash, cash equivalents and restricted cash $ 9,517 $ 13,356 Financial Instruments The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. Right-of-use asset Right-of-use assets represent an operating lease for office facilities. The right-of-use assets are reduced over the remaining term of the applicable lease ( April 2026) Lease liability The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 No. 2016 02, Leases no December 31, 2023 2022 December 31, 2023 2022 In March 2019, April 2026, A summary of the Company's expected operating lease cash flows at December 31, 2023 Operating lease payments Expected sublease receipts (In thousands) 2024 $ 613 $ 573 2025 619 590 2026 207 199 2027 — — 2028 — — Thereafter — — Total future minimum lease payments 1,439 1,362 Less imputed interest (190 ) Total operating lease liabilities $ 1,249 Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not Income Taxes The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not not Net Income (Loss) Per Share The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies. Segment Information The Company operates as one |
Note 2 - Ownership Interests an
Note 2 - Ownership Interests and Advances | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | 2. The following summarizes the carrying value of the Company’s ownership interests and advances. December 31, 2023 December 31, 2022 (In thousands) Equity Method: Companies $ 8,400 $ 8,749 Private equity funds 97 97 8,497 8,846 Other Method: Companies, fair value — 860 Companies, fair value measurement alternative 2,555 1,067 Private equity funds, fair value measurement alternative 250 250 2,805 2,177 Advances to companies 389 4,382 $ 11,691 $ 15,405 During the year ended December 31, 2023, December 31, 2022. 3 During 2023, 2022 2021 In September 2022, December 31, 2022. During the year ended December 31, 2022, 2021 As of December 31, 2023 4 Certain of the Company’s ownership interests as of December 31, 2023 2022 Safeguard Primary Ownership as of December 31, Company Name 2023 2022 Accounting Method as of December 31, 2023 Clutch Holdings, Inc. 41.7 % 41.7 % Equity InfoBionic, Inc. * 25.2 % Other MedCrypt, Inc. * * Other meQuilibrium 30.2 % 31.3 % Equity Moxe Health Corporation 19.3 % 19.3 % Equity Prognos Health Inc. 19.0 % 28.4 % Equity *minimal ownership interest Summarized Financial Information The following table provides summarized financial information for ownership interests accounted for under the equity method for the periods presented and has been compiled from respective company financial statements, reflect certain historical adjustments, and are reported on a one not As of December 31, 2023 2022 (In thousands) Balance Sheets: Current assets $ 49,546 $ 126,042 Non-current assets 9,892 55,073 Total assets $ 59,438 $ 181,115 Current liabilities $ 32,461 $ 92,990 Non-current liabilities 42,370 220,681 Shareholders’ deficit (15,393 ) (132,556 ) Total liabilities and shareholders’ deficit $ 59,438 $ 181,115 Number of equity method ownership interests 4 8 Year Ended December 31, 2023 2022 (In thousands) Results of Operations: Revenue $ 101,021 $ 144,771 Gross profit $ 71,529 $ 88,666 Net loss $ (73,913 ) $ (152,936 ) As of December 31, 2023 |
Note 3 - Acquisitions of Owners
Note 3 - Acquisitions of Ownership Interests | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Equity Method and Other Investments Disclosure [Text Block] | 3. 2023 The Company deployed $3.0 million to Prognos Health during the three June 30, 2023. The Company funded $0.3 million of convertible loans to Trice Medical during the three March, 31 2023. three September 30, 2023, During the three September 30, 2023, 2022 The Company funded $1.6 million of convertible loans to Syapse, Inc. The Company had previously deployed an aggregate of $25.0 million. Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models. The Company funded $2.0 million of convertible loans to Prognos Health Inc. The Company had previously deployed an aggregate of $12.6 million. The Company funded $1.4 million of convertible loans to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $16.9 million. Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base. The Company funded $0.5 million of convertible loans to meQuilibrium. The Company had previously deployed an aggregate of $14.0 million. meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers, and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being. The Company funded $0.1 million of convertible loans to Trice Medical. The Company had previously deployed an aggregate of $11.8 million. The Company also committed to provide another $0.3 million under certain conditions pursuant to a subordinated line of credit. At December 31, 2022, December 31, 2023, |
Note 4 - Fair Value Measurement
Note 4 - Fair Value Measurements | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 4. The Company categorizes its financial instruments into a three 1 3 Cash, cash equivalents and restricted cash approximate fair value due to their short term nature. The Company did not 2 3 December 31, 2023 Carrying Fair Value Measurement at December 31, 2023 Value Level 1 Level 2 Level 3 (in thousands) Cash and cash equivalents $ 9,498 $ 9,498 $ — $ — Restricted cash $ 19 $ 19 $ — $ — Carrying Fair Value Measurement at December 31, 2022 Value Level 1 Level 2 Level 3 (In thousands) Cash and cash equivalents $ 13,331 $ 13,331 $ — $ — Restricted cash $ 25 $ 25 $ — $ — Marketable securities—held-to-maturity: U.S. Government securities $ 5,956 $ 5,956 $ — $ — Ownership interests $ 860 $ 860 $ — $ — Ownership interests accounted for at fair value as of December 31, 2022 |
Note 5 - Equity
Note 5 - Equity | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | 5. In July 2015, December 31, 2023 2022 not In May 2021, "2021 10b5 1 10b 18 1934, December 31, 2021, 2021 October 2021, 2021 In March 2022, 2021 "2022 10b5 1 10b 18 1934, December 31, 2022, 2022 2022 January 2023 2022 |
Note 6 - Stock-Based Compensati
Note 6 - Stock-Based Compensation | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 6. Equity Compensation Plans The 2014 2023 2022 no first December 31, 2023 2014 Classification of Stock-Based Compensation Expense Stock-based compensation consists of time based awards to employees, financial liability based awards to employees and non-employees to be settled in stock, performance based awards to employees, and financial liability based awards to Directors for quarterly and annual services. Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: Year Ended December 31, 2023 2022 (In thousands) General and administrative expense $ 1,121 $ 1,445 $ 1,121 $ 1,445 Stock-based compensation expense of $1.1 million and $1.4 million was recognized during the years ended December 31, 2023 2022 December 31, 2023 2022 one 65 December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 The Company has previously granted certain performance-based stock units that vest based on the achievement of targeted capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified companies. The requisite service periods for these performance-based awards were based on the Company’s estimate of when the performance conditions will be met. Compensation expense was recognized for performance-based awards for which the performance condition is considered probable of achievement. During the years ended December 31, 2023 2022 zero January 2022, may one one December 31, 2022, Unrecognized compensation expense related to performance stock units and restricted stock at December 31, 2023 While there were no 2023 2022 two 1 2 Performance-based option awards also entitled participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company upon the sale, merger or other exit transaction of certain identified companies. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated. The Company did not December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 zero Service-based awards generally vest over four eight December 31, 2023 2022 zero December 31, 2023 2022 Option activity of the Company is summarized below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (In thousands) (In years) (In thousands) Outstanding at January 1, 2022 29 14.20 Options granted — — Options exercised — — Options canceled/forfeited (11 ) 14.48 Outstanding at December 31, 2022 18 14.05 Options granted — — Options exercised — — Options canceled/forfeited (10 ) 17.11 Outstanding at December 31, 2023 8 10.37 0.39 $ — Options exercisable at December 31, 2023 8 10.37 0.39 — Shares available for future grant 1,482 At December 31, 2023 December 31, 2023 Deferred stock unit, performance-based stock unit and restricted stock activity are summarized below: Shares Weighted Average Grant Date Fair Value (In thousands) Unvested at January 1, 2022 202 $ 9.70 Granted 343 5.60 Vested (293 ) 5.77 Forfeited (92 ) 13.90 Unvested at December 31, 2022 160 5.70 Granted 678 2.30 Vested (640 ) 2.90 Forfeited (16 ) 7.10 Unvested at December 31, 2023 182 1.89 |
Note 7 - Employee Benefit Plan
Note 7 - Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | 7. n The Company maintains a qualified 401 first December 31, 2023 2022 |
Note 8 - Income Taxes
Note 8 - Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 8. The federal and state provision (benefit) for income taxes was $0.0 million for the years ended December 31, 2023 2022 The total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal income tax rate of 21.0% for the years ended December 31, 2023 2022 Year Ended December 31, 2023 2022 Statutory tax expense (benefit) (21.0 )% (21.0 )% Increase (decrease) in taxes resulting from: Nondeductible expenses (0.4 ) (2.6 ) Valuation allowance 21.4 23.6 0.0 % 0.0 % The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: As of December 31, 2023 2022 (In thousands) Deferred tax asset: Carrying values of ownership interests and other holdings $ 24,370 $ 33,222 Tax loss and credit carryforwards 69,638 68,492 Disallowed interest carryforwards 6,613 6,891 Accrued expenses 13 47 Stock-based compensation (3 ) 180 Other 66 (106 ) 100,697 108,726 Valuation allowance (100,697 ) (108,726 ) Net deferred tax asset $ — $ — As of December 31, 2023 Total (In thousands) 2024 $ 50,140 2025 17,408 2026 7,648 2027 15,100 2028 and thereafter 182,520 $ 272,816 In assessing the recoverability of deferred tax assets, the Company considers whether it is more likely than not not not may not The Company recognizes in its Consolidated Financial Statements the impact of a tax position if that position is more likely than not The Company does not twelve There were no changes in the Company’s uncertain tax positions for the years ended December 31, 2023 2022 The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. Tax years 2019 December 31, 2023 |
Note 9 - Net Income (Loss) Per
Note 9 - Net Income (Loss) Per Share | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 9. The calculations of net income (loss) per share were: Year Ended December 31, 2023 2022 (In thousands, except per share data) Basic: Net (loss) $ (9,828 ) $ (14,263 ) Weighted average common shares outstanding 16,221 16,337 Net (loss) per share $ (0.61 ) $ (0.87 ) Diluted: Net (loss) $ (9,828 ) $ (14,263 ) Weighted average common shares outstanding 16,221 16,337 Net (loss) per share $ (0.61 ) $ (0.87 ) Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs). If an equity method company has dilutive stock options, unvested restricted stock, DSUs, or warrants, diluted net income (loss) per share is computed by first Diluted income (loss) per share for the years ended December 31, 2023 2022 not • At December 31, 2023 2022 2023, 2022 • At December 31, 2023 2022 |
Note 10 - Related Party Transac
Note 10 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 10. In the normal course of business, the Company’s officers and employees hold board positions with companies in which the Company has a direct or indirect ownership interest. |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 11. The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not no one The Company has provided a guarantee, which is fully funded by escrowed funds held by a third December 31, 2023 one The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for "good reason". The Company has recorded severance expenses of $0.7 million during the year ended December 31, 2023, 2024. In 2018, February 2019 June 2020, January 2018. June 2020 first may first first second 60 December 31, 2023 2022 not December 31, 2023 2022 December 31, 2023 In June 2011, March 2012, July 2015 one 2014 one 2017, |
Note 12 - Supplemental Cash Flo
Note 12 - Supplemental Cash Flow Information | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Cash Flow, Supplemental Disclosures [Text Block] | 12. During the years ended December 31, 2023 2022 zero |
Note 13 - Segment Reporting
Note 13 - Segment Reporting | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 13. The Company operates as one As of December 31, 2023 2022 |
Note 14 - Selected Quarterly Fi
Note 14 - Selected Quarterly Financial Information (Unaudited) | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Quarterly Financial Information [Text Block] | 14. Three Months Ended March 31 June 30 September 30 December 31 (In thousands, except per share data) 2023: General and administrative expense $ 1,185 $ 1,186 $ 1,313 $ 1,999 Operating loss (1,185 ) (1,186 ) (1,313 ) (1,999 ) Other income (loss), net (9 ) (166 ) 1,661 551 Interest income 274 249 198 182 Equity income (loss), net (2,564 ) (1,759 ) 386 (3,148 ) Net income (loss) before income taxes (3,484 ) (2,862 ) 932 (4,414 ) Income tax benefit (expense) — — — — Net income (loss) $ (3,484 ) $ (2,862 ) $ 932 $ (4,414 ) Net income (loss) per share (a) Basic $ (0.22 ) $ (0.18 ) $ 0.06 $ (0.27 ) Diluted $ (0.22 ) $ (0.18 ) $ 0.06 $ (0.27 ) 2022: General and administrative expense $ 1,234 $ 1,146 $ 1,360 $ 1,035 Operating loss (1,234 ) (1,146 ) (1,360 ) (1,035 ) Other income (loss), net (1,997 ) 30 (1,012 ) (318 ) Interest income 101 145 230 318 Equity income (loss), net (3,579 ) 1,454 (1,022 ) (3,838 ) Net income (loss) before income taxes (6,709 ) 483 (3,164 ) (4,873 ) Income tax benefit (expense) — — — — Net income (loss) $ (6,709 ) $ 483 $ (3,164 ) $ (4,873 ) Net income (loss) per share (a) Basic $ (0.40 ) $ 0.03 $ (0.19 ) $ (0.30 ) Diluted $ (0.40 ) $ 0.03 $ (0.19 ) $ (0.30 ) (a) Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not may not |
Note 15 - Subsequent Events
Note 15 - Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 15. On January 12, 2024, 1 1 |
Insider Trading Arrangements
Insider Trading Arrangements | 12 Months Ended |
Dec. 31, 2023 | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 9B. Other Information None. |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Principles of Consolidation The consolidated financial statements include the accounts of Safeguard and all of its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. |
Investment, Policy [Policy Text Block] | Principles of Accounting for Ownership Interests in Companies The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not third one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not not The Company accounts for ownership interests that are not December 31, 2023 no |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Income (loss) During the years ended December 31, 2023 2022, no |
Use of Estimates, Policy [Policy Text Block] | Accounting Estimates The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2023 not no not not |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid instruments with an original maturity of 90 not not |
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] | Restricted Cash Restricted cash represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Cash Flows: December 31, 2023 December 31, 2022 (In thousands) Cash and cash equivalents $ 9,498 $ 13,331 Restricted cash 19 25 Total cash, cash equivalents and restricted cash $ 9,517 $ 13,356 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Financial Instruments The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. |
Right-of-use Assets [Policy Text Block] | Right-of-use asset Right-of-use assets represent an operating lease for office facilities. The right-of-use assets are reduced over the remaining term of the applicable lease ( April 2026) |
Lessee, Leases [Policy Text Block] | Lease liability The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 No. 2016 02, Leases no December 31, 2023 2022 December 31, 2023 2022 In March 2019, April 2026, A summary of the Company's expected operating lease cash flows at December 31, 2023 Operating lease payments Expected sublease receipts (In thousands) 2024 $ 613 $ 573 2025 619 590 2026 207 199 2027 — — 2028 — — Thereafter — — Total future minimum lease payments 1,439 1,362 Less imputed interest (190 ) Total operating lease liabilities $ 1,249 |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not not |
Earnings Per Share, Policy [Policy Text Block] | Net Income (Loss) Per Share The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies. |
Segment Reporting, Policy [Policy Text Block] | Segment Information The Company operates as one |
Note 1 - General (Tables)
Note 1 - General (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Restrictions on Cash and Cash Equivalents [Table Text Block] | December 31, 2023 December 31, 2022 (In thousands) Cash and cash equivalents $ 9,498 $ 13,331 Restricted cash 19 25 Total cash, cash equivalents and restricted cash $ 9,517 $ 13,356 |
Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] | Operating lease payments Expected sublease receipts (In thousands) 2024 $ 613 $ 573 2025 619 590 2026 207 199 2027 — — 2028 — — Thereafter — — Total future minimum lease payments 1,439 1,362 Less imputed interest (190 ) Total operating lease liabilities $ 1,249 |
Note 2 - Ownership Interests _2
Note 2 - Ownership Interests and Advances (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block] | December 31, 2023 December 31, 2022 (In thousands) Equity Method: Companies $ 8,400 $ 8,749 Private equity funds 97 97 8,497 8,846 Other Method: Companies, fair value — 860 Companies, fair value measurement alternative 2,555 1,067 Private equity funds, fair value measurement alternative 250 250 2,805 2,177 Advances to companies 389 4,382 $ 11,691 $ 15,405 |
Schedule of Other Ownership Interests [Table Text Block] | Safeguard Primary Ownership as of December 31, Company Name 2023 2022 Accounting Method as of December 31, 2023 Clutch Holdings, Inc. 41.7 % 41.7 % Equity InfoBionic, Inc. * 25.2 % Other MedCrypt, Inc. * * Other meQuilibrium 30.2 % 31.3 % Equity Moxe Health Corporation 19.3 % 19.3 % Equity Prognos Health Inc. 19.0 % 28.4 % Equity |
Equity Method Investment Partner Company Results Of Operation [Table Text Block] | As of December 31, 2023 2022 (In thousands) Balance Sheets: Current assets $ 49,546 $ 126,042 Non-current assets 9,892 55,073 Total assets $ 59,438 $ 181,115 Current liabilities $ 32,461 $ 92,990 Non-current liabilities 42,370 220,681 Shareholders’ deficit (15,393 ) (132,556 ) Total liabilities and shareholders’ deficit $ 59,438 $ 181,115 Number of equity method ownership interests 4 8 |
Equity Method Investments [Table Text Block] | Year Ended December 31, 2023 2022 (In thousands) Results of Operations: Revenue $ 101,021 $ 144,771 Gross profit $ 71,529 $ 88,666 Net loss $ (73,913 ) $ (152,936 ) |
Note 4 - Fair Value Measureme_2
Note 4 - Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Carrying Fair Value Measurement at December 31, 2023 Value Level 1 Level 2 Level 3 (in thousands) Cash and cash equivalents $ 9,498 $ 9,498 $ — $ — Restricted cash $ 19 $ 19 $ — $ — Carrying Fair Value Measurement at December 31, 2022 Value Level 1 Level 2 Level 3 (In thousands) Cash and cash equivalents $ 13,331 $ 13,331 $ — $ — Restricted cash $ 25 $ 25 $ — $ — Marketable securities—held-to-maturity: U.S. Government securities $ 5,956 $ 5,956 $ — $ — Ownership interests $ 860 $ 860 $ — $ — |
Note 6 - Stock-Based Compensa_2
Note 6 - Stock-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Share-Based Payment Arrangement, Activity [Table Text Block] | Year Ended December 31, 2023 2022 (In thousands) General and administrative expense $ 1,121 $ 1,445 $ 1,121 $ 1,445 |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (In thousands) (In years) (In thousands) Outstanding at January 1, 2022 29 14.20 Options granted — — Options exercised — — Options canceled/forfeited (11 ) 14.48 Outstanding at December 31, 2022 18 14.05 Options granted — — Options exercised — — Options canceled/forfeited (10 ) 17.11 Outstanding at December 31, 2023 8 10.37 0.39 $ — Options exercisable at December 31, 2023 8 10.37 0.39 — Shares available for future grant 1,482 |
Schedule Of Activity For Restricted Stock Units Deferred Stock Units And Performance Units [Table Text Block] | Shares Weighted Average Grant Date Fair Value (In thousands) Unvested at January 1, 2022 202 $ 9.70 Granted 343 5.60 Vested (293 ) 5.77 Forfeited (92 ) 13.90 Unvested at December 31, 2022 160 5.70 Granted 678 2.30 Vested (640 ) 2.90 Forfeited (16 ) 7.10 Unvested at December 31, 2023 182 1.89 |
Note 8 - Income Taxes (Tables)
Note 8 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ended December 31, 2023 2022 Statutory tax expense (benefit) (21.0 )% (21.0 )% Increase (decrease) in taxes resulting from: Nondeductible expenses (0.4 ) (2.6 ) Valuation allowance 21.4 23.6 0.0 % 0.0 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | As of December 31, 2023 2022 (In thousands) Deferred tax asset: Carrying values of ownership interests and other holdings $ 24,370 $ 33,222 Tax loss and credit carryforwards 69,638 68,492 Disallowed interest carryforwards 6,613 6,891 Accrued expenses 13 47 Stock-based compensation (3 ) 180 Other 66 (106 ) 100,697 108,726 Valuation allowance (100,697 ) (108,726 ) Net deferred tax asset $ — $ — |
Summary of Operating Loss Carryforwards [Table Text Block] | Total (In thousands) 2024 $ 50,140 2025 17,408 2026 7,648 2027 15,100 2028 and thereafter 182,520 $ 272,816 |
Note 9 - Net Income (Loss) Pe_2
Note 9 - Net Income (Loss) Per Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Year Ended December 31, 2023 2022 (In thousands, except per share data) Basic: Net (loss) $ (9,828 ) $ (14,263 ) Weighted average common shares outstanding 16,221 16,337 Net (loss) per share $ (0.61 ) $ (0.87 ) Diluted: Net (loss) $ (9,828 ) $ (14,263 ) Weighted average common shares outstanding 16,221 16,337 Net (loss) per share $ (0.61 ) $ (0.87 ) |
Note 14 - Selected Quarterly _2
Note 14 - Selected Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Quarterly Financial Information [Table Text Block] | Three Months Ended March 31 June 30 September 30 December 31 (In thousands, except per share data) 2023: General and administrative expense $ 1,185 $ 1,186 $ 1,313 $ 1,999 Operating loss (1,185 ) (1,186 ) (1,313 ) (1,999 ) Other income (loss), net (9 ) (166 ) 1,661 551 Interest income 274 249 198 182 Equity income (loss), net (2,564 ) (1,759 ) 386 (3,148 ) Net income (loss) before income taxes (3,484 ) (2,862 ) 932 (4,414 ) Income tax benefit (expense) — — — — Net income (loss) $ (3,484 ) $ (2,862 ) $ 932 $ (4,414 ) Net income (loss) per share (a) Basic $ (0.22 ) $ (0.18 ) $ 0.06 $ (0.27 ) Diluted $ (0.22 ) $ (0.18 ) $ 0.06 $ (0.27 ) 2022: General and administrative expense $ 1,234 $ 1,146 $ 1,360 $ 1,035 Operating loss (1,234 ) (1,146 ) (1,360 ) (1,035 ) Other income (loss), net (1,997 ) 30 (1,012 ) (318 ) Interest income 101 145 230 318 Equity income (loss), net (3,579 ) 1,454 (1,022 ) (3,838 ) Net income (loss) before income taxes (6,709 ) 483 (3,164 ) (4,873 ) Income tax benefit (expense) — — — — Net income (loss) $ (6,709 ) $ 483 $ (3,164 ) $ (4,873 ) Net income (loss) per share (a) Basic $ (0.40 ) $ 0.03 $ (0.19 ) $ (0.30 ) Diluted $ (0.40 ) $ 0.03 $ (0.19 ) $ (0.30 ) |
Note 1 - General (Details Textu
Note 1 - General (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash and Cash Equivalents, at Carrying Value | $ 9,498 | $ 13,331 |
Lessee, Operating Lease, Discount Rate | 12% | |
Operating Lease, Cost | $ 500 | |
Operating Lease, Payments | $ 600 |
Note 1 - General - Schedule of
Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Cash and Cash Equivalents, at Carrying Value | $ 9,498 | $ 13,331 | |
Restricted cash | 19 | 25 | |
Total cash, cash equivalents and restricted cash | $ 9,517 | $ 13,356 | $ 24,764 |
Note 1 - General - Schedule o_2
Note 1 - General - Schedule of Leases (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
2024, operating lease payments | $ 613 |
2024, expected sublease receipts | 573 |
2025, operating lease payments | 619 |
2025, expected sublease receipts | 590 |
2026, operating lease payments | 207 |
2026, expected sublease receipts | 199 |
2027, operating lease payments | 0 |
2027, expected sublease receipts | 0 |
2028, operating lease payments | 0 |
2028, expected sublease receipts | 0 |
Thereafter, operating lease payments | 0 |
Thereafter, expected sublease receipts | 0 |
Total future minimum lease payments, operating lease payments | 1,439 |
Total future minimum lease payments, expected sublease receipts | 1,362 |
Less imputed interest | (190) |
Total operating lease liabilities | $ 1,249 |
Note 2 - Ownership Interests _3
Note 2 - Ownership Interests and Advances (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Equity Method Investment Assets Exceed Carrying Value Of Investment | $ 1,100 | |
Goodwill [Member] | ||
Equity Method Investment Allocation of Excess Fair Value | 1,000 | |
Intangible Assets [Member] | ||
Equity Method Investment Allocation of Excess Fair Value | 100 | |
Moxe Health Corporation [Member] | ||
Equity Method Investment, Other than Temporary Impairment | 1,000 | $ 0 |
Lumesis, Inc. [Member] | ||
"Equity Method Investment, Realized Gain (Loss) on Disposal, Other Receivable Related to Indemnification Escrow | 900 | 800 |
Proceeds from Sale of Equity Method Investments | 5,500 | |
Equity Method Investment, Realized Gain (Loss) on Disposal | 4,900 | |
Bright Health Group [Member] | ||
Proceeds From Fair Value Other Method Company | 800 | |
Flashtalking, Inc. [Member] | ||
Contingent Proceeds from Other Method Investment | 500 | |
Aktana, Inc. [Member] | ||
Contingent Proceeds from Other Method Investment | $ 400 | |
WebLinc, Inc. [Member] | ||
Equity Method Investment, Realized Gain (Loss) on Disposal | $ 500 |
Note 2 - Ownership Interests _4
Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Equity Method Companies | $ 8,497 | $ 8,846 |
Ownership interests | 0 | 860 |
Other Method, fair value measurement alternative | 2,805 | 2,177 |
Advances to companies | 389 | 4,382 |
Investments and Advances to Affiliates, Current and Noncurrent | 11,691 | 15,405 |
Partnership Interest [Member] | ||
Equity Method Companies | 8,400 | 8,749 |
Ownership interests | 0 | 860 |
Other Method, fair value measurement alternative | 2,555 | 1,067 |
Private Equity Funds [Member] | ||
Equity Method Companies | 97 | 97 |
Other Method, fair value measurement alternative | $ 250 | $ 250 |
Note 2 - Ownership Interests _5
Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) | Dec. 31, 2023 | Dec. 31, 2022 |
Clutch Holdings [Member] | ||
Ownership Interest | 41.70% | 41.70% |
InfoBionic, Inc. [Member] | ||
Ownership Interest | 25.20% | |
meQuilibrium [Member] | ||
Ownership Interest | 30.20% | 31.30% |
Moxe Health Corporation [Member] | ||
Ownership Interest | 19.30% | 19.30% |
Prognos Health, Inc. [Member] | ||
Ownership Interest | 19% | 28.40% |
Note 2 - Ownership Interests _6
Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details) $ in Thousands | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) |
Current assets | $ 9,911 | $ 21,423 |
Total Assets | 22,836 | 37,692 |
Current liabilities | 2,046 | 1,817 |
Total Liabilities and Equity | 22,836 | 37,692 |
High Traction Stage [Member] | ||
Current assets | 49,546 | 126,042 |
Non-current assets | 9,892 | 55,073 |
Total Assets | 59,438 | 181,115 |
Current liabilities | 32,461 | 92,990 |
Non-current liabilities | 42,370 | 220,681 |
Shareholders’ deficit | (15,393) | (132,556) |
Total Liabilities and Equity | $ 59,438 | $ 181,115 |
Number of equity method ownership interests | 4 | 8 |
Note 2 - Ownership Interests _7
Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue | $ 101,021 | $ 144,771 |
Gross profit | 71,529 | 88,666 |
Net loss | $ (73,913) | $ (152,936) |
Note 3 - Acquisitions of Owne_2
Note 3 - Acquisitions of Ownership Interests (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | |
Payments to Acquire Equity Method Investments | $ 3,000 | $ 0 | |||
Equity Method Investments | 8,497 | 8,846 | |||
Prognos Health, Inc. [Member] | |||||
Payments to Acquire Equity Method Investments | $ 3,000 | ||||
Equity Method Investments | $ 14,600 | 12,600 | |||
Convertible Bridge Loan | 2,000 | ||||
Trice Medical, Inc. [Member] | |||||
Equity Method Investments | $ 12,000 | 11,800 | |||
Convertible Bridge Loan | $ 300 | 100 | |||
Trice Medical, Inc. [Member] | Equity Method Investee [Member] | Credit Facility [Member] | |||||
Commitment To Fund Convertible Bridge Loan | $ 300 | 300 | |||
InfoBionic, Inc. [Member] | |||||
Other Method Investment, Realized Gain (Loss) | $ 1,700 | ||||
InfoBionic, Inc. [Member] | Approximate [Member] | |||||
Other Method Investment, Ownership Percentage | 5% | ||||
Syapse, Inc. [Member] | |||||
Equity Method Investments | 25,000 | ||||
Convertible Bridge Loan | 1,600 | ||||
Clutch Holdings [Member] | |||||
Equity Method Investments | 16,900 | ||||
Convertible Bridge Loan | 1,400 | ||||
meQuilibrium [Member] | |||||
Equity Method Investments | 14,000 | ||||
Convertible Bridge Loan | $ 500 |
Note 4 - Fair Value Measureme_3
Note 4 - Fair Value Measurements (Details Textual) shares in Millions | Dec. 31, 2022 shares |
Bright Health [Member] | |
Investment Owned, Balance, Shares (in shares) | 1.3 |
Note 4 - Fair Value Measureme_4
Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Reported Value Measurement [Member] | ||
Cash and cash equivalents | $ 9,498 | $ 13,331 |
Restricted cash | 19 | 25 |
U.S. Government securities | 5,956 | |
Ownership interests | 860 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | 9,498 | 13,331 |
Restricted cash | 19 | 25 |
U.S. Government securities | 5,956 | |
Ownership interests | 860 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Restricted cash | 0 | 0 |
U.S. Government securities | 0 | |
Ownership interests | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Restricted cash | $ 0 | 0 |
U.S. Government securities | 0 | |
Ownership interests | $ 0 |
Note 5 - Equity (Details Textua
Note 5 - Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | ||||||
Jan. 31, 2023 | Oct. 31, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2022 | May 31, 2021 | Jul. 31, 2015 | |
Treasury Stock, Value, Acquired, Cost Method | $ 75 | $ 2,940 | ||||||
Share Repurchase Program Authorized in July 2015 [Member] | ||||||||
Stock Repurchase Program, Authorized Amount | $ 25,000 | |||||||
Treasury Stock, Shares, Acquired (in shares) | 0 | 0 | ||||||
Share Repurchase Program Authorized in May 2021 [Member] | ||||||||
Stock Repurchase Program, Authorized Amount | $ 6,000 | |||||||
Treasury Stock, Shares, Acquired (in shares) | 236,159 | |||||||
Treasury Stock, Value, Acquired, Cost Method | $ 1,600 | |||||||
Treasury Stock Acquired, Average Cost Per Share (in dollars per share) | $ 6.94 | |||||||
Dutch Auction Self-tender [Member] | ||||||||
Treasury Stock, Shares, Acquired (in shares) | 4,300,000 | |||||||
Treasury Stock, Value, Acquired, Cost Method | $ 38,700 | |||||||
Treasury Stock Acquired, Average Cost Per Share (in dollars per share) | $ 9 | |||||||
Share Repurchase Program Authorized in March 2022 [Member] | ||||||||
Stock Repurchase Program, Authorized Amount | $ 3,000 | |||||||
Treasury Stock, Shares, Acquired (in shares) | 25,096 | 711,481 | ||||||
Treasury Stock, Value, Acquired, Cost Method | $ 2,900 | |||||||
Treasury Stock Acquired, Average Cost Per Share (in dollars per share) | $ 4.09 | $ 4.13 |
Note 6 - Stock-Based Compensa_3
Note 6 - Stock-Based Compensation (Details Textual) shares in Thousands | 12 Months Ended | |
Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) shares | |
Share-Based Payment Arrangement, Expense | $ | $ 1,121,000 | $ 1,445,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Types | 2 | |
Director [Member] | ||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ | 0.1 | $ 400,000 |
Performance Shares [Member] | ||
Share-Based Payment Arrangement, Expense | $ | $ 1,100,000 | $ 1,400,000 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) | 92 | 0 |
Restricted Stock [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 125 | 22 |
Restricted Stock [Member] | Director [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) | 377 | 165 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 275 | 110 |
Restricted Stock [Member] | Other Management [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued and Vested in Period (in shares) | 51 | 82 |
Restricted Stock [Member] | Non-Employee [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued and Vested in Period (in shares) | 0 | 15 |
Performance Stock Unit [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) | 0 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 0 | |
Share-Based Payment Arrangement, Expense, after Tax | $ | $ 0 | |
Performance Based Options [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares (in shares) | 0 | 11 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares) | 0 | |
Service Based Award [Member] | ||
Share-Based Payment Arrangement, Expense, after Tax | $ | $ 0 | $ 0 |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | |
Share Based Compensation Arrangement, By Share Based Payment Award, Expiration Term (Year) | 8 years | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares) | 0 | 0 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares) | 10 | 0 |
2014 Equity Compensation Plan [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 4,100 | |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,500 | |
The 2020 Award [Member] | ||
Share-Based Payment Arrangement, Expense | $ | $ 200,000 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 64 |
Note 6 - Stock-based Compensa_4
Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Stock Based Compensation | $ 1,121 | $ 1,445 |
General and Administrative Expense [Member] | ||
Stock Based Compensation | $ 1,121 | $ 1,445 |
Note 6 - Stock-Based Compensa_5
Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Balance, shares (in shares) | 18 | 29 |
Balance, weighted average exercise price (in dollars per share) | $ 14.05 | $ 14.2 |
Options granted, shares (in shares) | 0 | 0 |
Options granted, weighted average exercise price (in dollars per share) | $ 0 | $ 0 |
Options exercised, shares (in shares) | 0 | 0 |
Options exercised, weighted average exercise price (in dollars per share) | $ 0 | $ 0 |
Options canceled/forfeited, shares (in shares) | (10) | (11) |
Options canceled/forfeited, weighted average exercise price (in dollars per share) | $ 17.11 | $ 14.48 |
Options exercised, shares (in shares) | 0 | 0 |
Balance, shares (in shares) | 8 | 18 |
Balance, weighted average exercise price (in dollars per share) | $ 10.37 | $ 14.05 |
Balance, weighted average remaining contractual life (Year) | 4 months 20 days | |
Balance, aggregative intrinsic value | $ 0 | |
Options exercisable, shares (in shares) | 8 | |
Options exercisable , weighted average exercise price (in dollars per share) | $ 10.37 | |
Options exercisable, weighted average remaining contractual life (Year) | 4 months 20 days | |
Options exercisable, aggregative intrinsic value | $ 0 | |
Shares available for future grant, shares (in shares) | 1,482 |
Note 6 - Stock-Based Compensa_6
Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details) - Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] - $ / shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Balance (in shares) | 160 | 202 |
Balance (in dollars per share) | $ 5.7 | $ 9.7 |
Granted (in shares) | 678 | 343 |
Granted (in dollars per share) | $ 2.3 | $ 5.6 |
Vested (in shares) | (640) | (293) |
Vested (in dollars per share) | $ 2.9 | $ 5.77 |
Forfeited (in shares) | (16) | (92) |
Forfeited (in dollars per share) | $ 7.1 | $ 13.9 |
Balance (in shares) | 182 | 160 |
Balance (in dollars per share) | $ 1.89 | $ 5.7 |
Note 7 - Employee Benefit Plan
Note 7 - Employee Benefit Plan (Details Textual) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Defined Contribution Plan, Employer Matching Contribution, Percent of Match | 100% | |
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 5% | |
Defined Contribution Plan, Cost | $ 0.1 | $ 0.1 |
Note 8 - Income Taxes (Details
Note 8 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Federal Income Tax Expense (Benefit), Continuing Operations | $ 0 | $ 0 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate (Negative Rate), Percent | (21.00%) | (21.00%) |
Deferred Tax Assets, Operating Loss Carryforwards | $ 332 | |
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration | 59 | |
Unrecognized Tax Benefits, Period Increase (Decrease) | $ 0 | $ 0 |
Note 8 - Income Taxes - Schedul
Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Statutory tax expense (benefit) | (21.00%) | (21.00%) |
Nondeductible expenses | (0.40%) | (2.60%) |
Valuation allowance | 21.40% | 23.60% |
Effective Income Tax Rate Reconciliation, Percent | 0% | 0% |
Note 8 - Income Taxes -Schedule
Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Carrying values of ownership interests and other holdings | $ 24,370 | $ 33,222 |
Tax loss and credit carryforwards | 69,638 | 68,492 |
Disallowed interest carryforwards | 6,613 | 6,891 |
Accrued expenses | 13 | 47 |
Stock-based compensation | (3) | |
Stock-based compensation | 180 | |
Other | 66 | (106) |
Deferred Tax Assets, Gross | 100,697 | 108,726 |
Valuation allowance | (100,697) | (108,726) |
Net deferred tax asset | $ 0 | $ 0 |
Note 8 - Income Taxes - Sched_2
Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
2024 | $ 50,140 |
2025 | 17,408 |
2026 | 7,648 |
2027 | 15,100 |
2028 and thereafter | 182,520 |
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | $ 272,816 |
Note 9 - Net Income (Loss) Pe_3
Note 9 - Net Income (Loss) Per Share (Details Textual) - $ / shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Share-Based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 8 | 18 |
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) | $ 10.37 | |
Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) | $ 10.37 | |
Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) | $ 17.11 | |
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 200 | 200 |
Note 9 - Net Income (Loss) Pe_4
Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||||||||
Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |||||||||
Basic: | ||||||||||||||||||
Net (loss) | $ (4,414) | $ 932 | $ (2,862) | $ (3,484) | $ (4,873) | $ (3,164) | $ 483 | $ (6,709) | $ (9,828) | $ (14,263) | ||||||||
Basic (in shares) | 16,221 | 16,337 | ||||||||||||||||
Basic (in dollars per share) | $ (0.27) | [1] | $ 0.06 | [1] | $ (0.18) | [1] | $ (0.22) | [1] | $ (0.3) | [1] | $ (0.19) | [1] | $ 0.03 | [1] | $ (0.4) | [1] | $ (0.61) | $ (0.87) |
Diluted: | ||||||||||||||||||
Net (loss) | $ (4,414) | $ 932 | $ (2,862) | $ (3,484) | $ (4,873) | $ (3,164) | $ 483 | $ (6,709) | $ (9,828) | $ (14,263) | ||||||||
Diluted (in shares) | 16,221 | 16,337 | ||||||||||||||||
Diluted (in dollars per share) | $ (0.27) | [1] | $ 0.06 | [1] | $ (0.18) | [1] | $ (0.22) | [1] | $ (0.3) | [1] | $ (0.19) | [1] | $ 0.03 | [1] | $ (0.4) | [1] | $ (0.61) | $ (0.87) |
[1]Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests. |
Note 11 - Commitments and Con_2
Note 11 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Guarantor Obligations, Current Carrying Value | $ 3,800 | |
Severance Costs | 700 | |
Long-term Incentive Plan, Payments | 0 | $ 0 |
Deferred Compensation Liability, Current and Noncurrent, Total | 0 | |
Amended and Restated Safeguard Scientifics Transaction Bonus Plan [Member] | ||
Compensation, Cash Award | $ 0 | $ 0 |
Minimum [Member] | ||
Long-term Incentive Plan, Bonus Pool Percent | 0.20% | 1% |
Maximum [Member] | ||
Long-term Incentive Plan, Bonus Pool Percent | 1.30% |
Note 12 - Supplemental Cash F_2
Note 12 - Supplemental Cash Flow Information (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Debt Conversion, Converted Instrument, Amount | $ 1,500 | $ 0 |
Note 13 - Segment Reporting (De
Note 13 - Segment Reporting (Details Textual) | 12 Months Ended |
Dec. 31, 2023 | |
Number of Operating Segments | 1 |
Note 14 - Selected Quarterly _3
Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||||||||
Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |||||||||
General and administrative expense | $ 1,999 | $ 1,313 | $ 1,186 | $ 1,185 | $ 1,035 | $ 1,360 | $ 1,146 | $ 1,234 | $ 5,683 | $ 4,775 | ||||||||
Operating loss | (1,999) | (1,313) | (1,186) | (1,185) | (1,035) | (1,360) | (1,146) | (1,234) | (5,683) | (4,775) | ||||||||
Other income (loss), net | 551 | 1,661 | (166) | (9) | (318) | (1,012) | 30 | (1,997) | 2,037 | (3,297) | ||||||||
Interest income | 182 | 198 | 249 | 274 | 318 | 230 | 145 | 101 | 903 | 794 | ||||||||
Equity income (loss), net | (3,148) | 386 | (1,759) | (2,564) | (3,838) | (1,022) | 1,454 | (3,579) | (7,085) | (6,985) | ||||||||
Net income (loss) before income taxes | (4,414) | 932 | (2,862) | (3,484) | (4,873) | (3,164) | 483 | (6,709) | (9,828) | (14,263) | ||||||||
Net income (loss) | $ (4,414) | $ 932 | $ (2,862) | $ (3,484) | $ (4,873) | $ (3,164) | $ 483 | $ (6,709) | $ (9,828) | $ (14,263) | ||||||||
Basic (in dollars per share) | $ (0.27) | [1] | $ 0.06 | [1] | $ (0.18) | [1] | $ (0.22) | [1] | $ (0.3) | [1] | $ (0.19) | [1] | $ 0.03 | [1] | $ (0.4) | [1] | $ (0.61) | $ (0.87) |
Diluted (in dollars per share) | $ (0.27) | [1] | $ 0.06 | [1] | $ (0.18) | [1] | $ (0.22) | [1] | $ (0.3) | [1] | $ (0.19) | [1] | $ 0.03 | [1] | $ (0.4) | [1] | $ (0.61) | $ (0.87) |
[1]Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests. |
Note 15 - Subsequent Events (De
Note 15 - Subsequent Events (Details Textual) - Subsequent Event [Member] $ in Thousands | Jan. 12, 2024 USD ($) shares |
Stock Repurchased and Retired During Period, Shares (in shares) | shares | 6,000 |
Stock Repurchased and Retired During Period, Value | $ | $ 9 |
Reverse Stock Split [Member] | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 100 |
Forward Stock Split [Member] | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 100 |